Pembrolizumab Monotherapy for the Treatment of High-Risk Non–Muscle Invasive Bladder Cancer Unresponsive to BCG
Read it now on PracticeUpdate.com
Read it now on PracticeUpdate.com
Enfortumab vedotin/pembrolizumab, gemcitabine-cisplatin/nivolumab, and the JAVELIN paradigm can all play a role as first-line therapy for appropriately selected patients with advanced urothelial carcinoma.
A video from Guru Sonpavde (as part of AdventHealth), posted on Apr 16, 2024.
Read it now on PracticeUpdate.com
Read it now on PracticeUpdate.com
Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting EV302 and CheckMate 901
The ESMO annual conference in 2023 brought the most remarkable advances in the first-line therapy of metastatic urothelial carcinoma (mUC) since th…
Read it now on PracticeUpdate.com
Read it now on PracticeUpdate.com
Read it now on PracticeUpdate.com
Read it now on PracticeUpdate.com